Innovative Treatments for Cancer Highlighted by BioAtla at AACR
BioAtla's Participation in the Upcoming AACR Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), an innovative clinical-stage biotechnology company, is excited to announce its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting. This prestigious event will take place in Chicago at the McCormick Place Convention Center, where BioAtla will present groundbreaking advancements in Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors.
Significant Presentations and Research Focus
During this year's meeting, two noteworthy abstracts will be featured as poster presentations which underscore the potential of BioAtla's proprietary CAB technology. The first research highlights an exciting development: a CAB anti-Nectin4-antibody drug conjugate (ADC) exhibiting remarkable preclinical efficacy in various cancer models, including lung, breast, pancreatic, and urothelial cancers. The significance of this finding cannot be overstated as it shows the potential to outperform existing therapies, like enfortumab vedotin.
Enhanced Safety and Efficacy
The CAB technology innovates treatment by providing a new class of biologics that target cancerous cells and related ailments with greater precision. This approach presents a promising future in cancer treatment, enhancing safety and effectiveness while minimizing adverse effects. With CAB, researchers are exploring fresh pathways to address cancer and aging-related diseases by properly targeting senescence-associated cells.
Poster Presentation Details
BioAtla's presentations are set to capture the attention of attendees at the AACR event. Below are some essential details:
First Poster Presentation
Title: Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo
Authors: Jian Chen, Jing Wang, Haizhen Liu, Gerhard Frey, Cathy Chang, William J. Boyle, and Jay M. Short
Poster Number: 5
Session Title: Molecular/Cellular Biology and Genetics / Senescence
Date/Time: April 27, 2025; 2:00–5:00 PM CDT
Location: Poster Section 13
Second Poster Presentation
Title: BA3361, A Tumor Selective, Conditionally Active Biologic (CAB) anti-Nectin4-ADC with a Novel NextGen Linker System Enhances Therapeutic Efficacy in Pancreatic Cancer
Authors: Jing Wang, Jian Chen, Gerhard Frey, Haizhen Liu, Charles Xing, Kathryn Woodard, Cathy Chang, William J. Boyle, and Jay M. Short
Poster Number: 10
Session Title: Tumor Biology / Targeting the Tumor Microenvironment: A Brave New World
Date/Time: April 28, 2025; 2:00–5:00 PM CDT
Location: Poster Section 7
About BioAtla
BioAtla, Inc. is a pioneering biotechnology firm with a commitment to developing robust antibody therapeutics. With locations in San Diego and a partnership in Beijing through BioDuro-Sundia, BioAtla focuses on the advancement of its CAB technology platform. This unique platform facilitates the creation of monoclonal and bispecific antibodies intended to enhance targeting specificity, efficacy, and manufacturing efficiency compared to traditional treatments.
The company boasts extensive global patent coverage, with over 780 active patent matters, ensuring robust protection for its technological innovations. BioAtla is currently advancing several clinical programs, including its first dual CAB bispecific T-cell engager antibody, BA3182, which is undergoing an initial Phase 1 trial. Additionally, its first-in-class CAB programs, including mecbotamab vedotin and ozuriftamab vedotin, are making strides in Phase 2 trials. Furthermore, the novel CTLA-4 inhibitor, evalstotug, aims to reduce toxicity and improve safety in conjunction with checkpoint inhibitors.
Contact Information
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
Email: rwaldron@bioatla.com
Phone: 858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
Email: bmackle@lifesciadvisors.com
Frequently Asked Questions
What is the focus of BioAtla's research presented at AACR?
BioAtla's presentations focus on innovative CAB antibody therapeutics aimed at solid tumors.
When and where will the AACR Annual Meeting be held?
The AACR Annual Meeting will take place in April 2025 at the McCormick Place Convention Center in Chicago.
What is the significance of CAB technology?
CAB technology enhances cancer treatments by specifically targeting diseased cells while ensuring a better safety profile.
How many abstracts has BioAtla submitted for presentation?
BioAtla has submitted two abstracts for poster presentations at the AACR meeting.
What are the current clinical trials BioAtla is conducting?
BioAtla is conducting clinical trials for its CAB programs, including BA3182, mecbotamab vedotin, and ozuriftamab vedotin in advanced stages.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.